Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database

doi:10.1515/med-2021-0215

	Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database
	Lei, Lei 2; Yang, Liu 4; Xu, Yang-yang 4; Chen, Hua-fei 2; Zhan, Ping 3; Wang, Wen-xian 1; Xu, Chun-wei 3
刊名	OPEN MEDICINE
	2021
卷号	16
关键词	NSCLC HAL SEER survival
ISSN号	2391-5463
DOI	10.1515/med-2021-0215
通讯作者	Chen, Hua-fei(59715441@qq.com) ; Wang, Wen-xian(helen-0407@163.com) ; Xu, Chun-wei(xuchunweibbb@163.com)
英文摘要	Hepatoid adenocarcinoma of the lung (HAL) is a rare malignant tumor that is defined as a primary alpha-fetoprotein (AFP)-producing lung carcinoma. We aimed to identify prognostic factors associated with the survival of patients with HAL using data from the Surveillance, Epidemiology, and End Results (SEER) database. We collected data from patients diagnosed with HAL, adenocarcinoma (ADC), and squamous cell carcinoma (SCC) of the lung between 1975 and 2016 from the SEER database. The clinical features of patients with ADC and SCC of the lung were also analyzed. The clinical features of HALs were compared to ADCs and SCCs. A chi-square test was used to calculate the correlations between categorical variables, and a t test or Mann-Whitney U test was used for continuous variables. The Kaplan-Meier method and Cox regression analysis were used to identify the prognostic factors for the overall survival (OS) of HALs. Two-tailed p values < 0.05 were considered statistically significant. Sixty-five patients with HAL, 2,84,379 patients with ADC, and 1,86,494 with SCC were identified from the SEER database. Fewer males, advanced stages, and more chemotherapy-treated HALs were found. Compared to patients with SCC, patients with HAL were less likely to be male, more likely to be in an advanced stage, and more likely to receive chemotherapy (p < 0.05). The American Joint Committee on Cancer staging was the only prognostic factor for OS in patients with HAL, and stage IV was significantly different from other stages (hazard ratio = 0.045, 95% confidence interval: 0.005-0.398, p = 0.005). Males with HAL were more likely to receive radiotherapy compared to females with HAL (61.8 vs 31.5%, p = 0.034). Younger patients with HAL were more likely to receive chemotherapy (59.4 + 10.2 years vs 69 + 11.3 years, p = 0.001). The primary tumor size of HAL was associated with the location of the primary lesion (p = 0.012). No conventional antitumor therapies, including surgery, chemotherapy, and radiotherapy, were shown to have a significant survival benefit in patients with HAL (p > 0.05). This study showed that stage IV was the only prognostic factor for OS in HALs compared to other clinicopathologic factors. Conventional antitumor therapies failed to show survival benefit; thus, a more effective method by which to treat HAL is needed. Interestingly, the clinical features and the location of the primary lesion were shown to be associated with primary a tumor size and treatment in patients with HAL, which have not been reported before.
资助项目	Medical Scientific Research Foundation of Zhejiang Province of China[2019RC027] ; Zhejiang Traditional Chinese Medicine Science Fund Project[2020ZB037] ; Zhejiang Traditional Chinese Medicine Science Fund Project[2020ZQ013] ; Scientific Research Foundation of Zhejiang Medical Association[2019ZYC-A76] ; Huilan Public-Hanson Pharmaceutical Lung Cancer PrecisionMedical Research Special Fund Project Foundation[HL-HS2020-5] ; Xisike-Hanson Cancer Research Foundation[Y-HS2019-20]
WOS关键词	CARCINOMA ; METASTASIS
WOS研究方向	General & Internal Medicine
语种	英语
出版者	DE GRUYTER POLAND SP Z O O
WOS记录号	WOS:000617108900004
资助机构	Medical Scientific Research Foundation of Zhejiang Province of China ; Zhejiang Traditional Chinese Medicine Science Fund Project ; Scientific Research Foundation of Zhejiang Medical Association ; Huilan Public-Hanson Pharmaceutical Lung Cancer PrecisionMedical Research Special Fund Project Foundation ; Xisike-Hanson Cancer Research Foundation
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/131285]
专题	中国科学院合肥物质科学研究院
通讯作者	Chen, Hua-fei; Wang, Wen-xian; Xu, Chun-wei
作者单位	1.Univ Chinese Acad Sci, Inst Canc Res & Basic Med Sci, Chinese Acad Sci, Canc Hosp,Zhejiang Canc Hosp,Dept Chemotherapy, 1 Banshan East St, Hangzhou 310022, Zhejiang, Peoples R China 2.Zhejiang Rongjun Hosp, Dept Thorac Dis Ctr, 589 Cent West Rd, Jiaxing 314000, Zhejiang, Peoples R China 3.Nanjing Univ, Affiliated Jinling Hosp, Dept Resp Med, Med Sch, 305 Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China 4.Shanghai Dunlu Biomed Technol Co Ltd, Dept Med, Shanghai 200032, Peoples R China
推荐引用方式 GB/T 7714	Lei, Lei,Yang, Liu,Xu, Yang-yang,et al. Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database[J]. OPEN MEDICINE,2021,16.
APA	Lei, Lei.,Yang, Liu.,Xu, Yang-yang.,Chen, Hua-fei.,Zhan, Ping.,...&Xu, Chun-wei.(2021).Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database.OPEN MEDICINE,16.
MLA	Lei, Lei,et al."Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database".OPEN MEDICINE 16(2021).